J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

J&J has long had high hopes for its an­ti-in­flam­ma­to­ry IL-23 drug guselkum­ab. And to­day in Vi­en­na they de­tailed the first round of Phase III da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.